Renal GLUT1 reduction depends on angiotensin-converting enzyme inhibition in diabetic hypertensive rats


Autoria(s): Silva, Ariel S. da; Dias, Lucinara D.; Borges, Júlia F.; Markoski, Melissa M.; Souza, Martina S. de; Irigoyen, Maria Claudia Costa; Machado, Ubiratan Fabres; Schaan, Beatriz D.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

04/04/2014

04/04/2014

10/07/2013

Resumo

Aims: Angiotensin-converting enzyme (ACE) inhibitors are used in diabetic kidney disease to reduce systemic/intra-glomerular pressure. The objective of this study was to investigate whether reducing blood pressure (BP) could modulate renal glucose transporter expression, and urinary markers of diabetic nephropathy in diabetic hypertensive rats treated with ramipril or amlodipine. Main methods: Diabetes was induced in spontaneously-hypertensive rats (~210 g) by streptozotocin (50 mg/kg). Thirty days later, animals received ramipril 15 μg/kg/day (R, n =10), or amlodipine 10 mg/kg/day (A, n= 8,) or water (C, n = 10) by gavage. After 30-day treatment, body weight, glycaemia, urinary albumin and TGF-β1 (enzyme-linked immunosorbent assay) and BP (tail-cuff pressure method) were evaluated. Kidneys were removed for evaluation of renal cortex glucose transporters (Western blotting) and renal tissue ACE activity (fluorometric assay). Key findings: After treatments, body weight (p = 0.77) and glycaemia (p = 0.22) were similar among the groups. Systolic BP was similarly reduced (p < 0.001) in A and R vs. C (172.4 ± 3.2; 186.7 ± 3.7 and 202.2 ± 4.3 mm Hg; respectively). ACE activity (C: 0.903 ± 0.086; A: 0.654 ± 0.025, and R: 0.389 ± 0.057 mU/mg), albuminuria (C: 264.8 ± 15.4; A: 140.8 ± 13.5 and R: 102.8 ± 6.7 mg/24 h), and renal cortex GLUT1 content (C: 46.81 ± 4.54; A: 40.30 ± 5.39 and R: 26.89 ± 0.79 AU) decreased only in R (p < 0.001, p < 0.05 and p < 0.001; respectively). Significance:We concluded that the blockade of the renin–angiotensin systemwith ramipril reduced earlymarkers of diabetic nephropathy, a phenomenon that cannot be specifically related to decreased BP levels.

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fundação de Apoio à pesquisa do Rio Grande do Sul (FAPERGS)

Fundo de Apoio à Pesquisa do Instituto de Cardiologia (FAPICC)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP, 2012/04831-1)

Identificador

Life Sciences, Oxford, v.92, n.24-26, p.1174-1179, 2013

http://www.producao.usp.br/handle/BDPI/44384

10.1016/j.lfs.2013.05.001

http://dx.doi.org/10.1016/j.lfs.2013.05.001

Idioma(s)

eng

Publicador

Pergamon Press

Oxford

Relação

Life Sciences

Direitos

restrictedAccess

Elsevier Inc.

Palavras-Chave #Angiotensin-converting enzyme inhibitors #Diabetes mellitus #Diabetic nephropathy #Glucose transporter proteins #Hypertension #Streptozotocin #Diabetes mellitus #Nefropatias #Hipertensão #Pressão sanguínea
Tipo

article

original article

publishedVersion